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ABSTRACT
This article brieﬂy summarises the arguments for and against the routine use of rapid antigen testing for
group A b-haemolytic streptococcal pharyngitis and the deﬁciencies in the current evidence base in this
area. Currently, most commercial tests are immunoassays with a sensitivity of 70–95% (average 85%)
and a speciﬁcity of 95–99%, depending on the comparator and patient population. Rapid antigen testing
is recommended and commonly used in the USA, especially for patients in whom group A b-haemolytic
streptococcal infection is clinically likely or who have any symptoms plus direct contact exposure.
However, there is no consensus in Europe regarding the role of rapid testing. There remains a need for
randomised trials to evaluate its beneﬁt to patients and its cost-effectiveness compared with the main
alternatives, including delayed antibiotic prescribing.
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INTRODUCTION
There remains substantial overuse of antibiotics for
the treatment of sore throat in both children and
adults. In the USA, it is estimated that antibiotics
were prescribed during 54% of ofﬁce, hospital
outpatient department and emergencydepartment
visits for children with sore throat [1]. This repre-
sents a signiﬁcant reduction from the correspond-
ing rate of 66% of visits in 1995 [1]. However, it still
exceeds the percentage of sore throat cases typic-
ally caused by group A b-haemolytic streptococci
(GABHS, i.e., Streptococcus pyogenes), which is
approximately 15–30% in children [2–4]. In adults,
antibioticswere prescribed during 73% of visits for
sore throat in 2001 [5], while only 5–10% of cases
are caused by GABHS [2–4].
Acute streptococcal pharyngitis is a distressing
condition, but in most patients is a benign and
self-limited illness. Antibiotic therapy given early
can decrease the duration of symptoms and allow
earlier return to contact with others, thus decreas-
ing isolation times and resulting in reduced
transmission of the illness [6]. Another principal
driver of early treatment is the aim to decrease
time lost at work and school. It is desirable to treat
cases of group A b-haemolytic streptococcal
pharyngitis to decrease the risk of rheumatic
fever and possibly to decrease suppurative com-
plications such as peritonsillar abscess. Empirical
antibiotic therapy, early treatment based on rapid
antigen testing for GABHS and delayed treatment
within 4 days of positive cultures all accomplish
this with regard to the risk of rheumatic fever.
Rapid antigen testing has largely supplanted
microbiological culturing as the initial test of
choice for detecting streptococcal pharyngitis in
the USA [7]. This has occurred because both
practitioners and patients prefer to have results
earlier and to initiate treatment sooner. However,
there is substantial international variation in the
usage of rapid streptococcal tests, as well as in the
usage of antibiotic therapy, for pharyngitis. Both
are used more commonly in the USA than in the
UK, and substantial variation also exists among
European countries.
A number of criteria need to be considered to
determine whether near-patient tests should be
used, including the test’s ease of use by clinicians
and acceptability to patients, its validity, and its
cost-effectiveness compared with alternative
management strategies. This article brieﬂy sum-
marises the arguments for and against the routine
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use of rapid antigen testing for streptococcal
pharyngitis and the deﬁciencies in the current
evidence base in this area.
VALIDITY: CARRIER STATE VS.
INFECTION
For a mainly benign condition such as sore throat,
speciﬁcity is arguably as important as sensitivity,
although the literature has mainly concentrated on
maximising sensitivity. Importantly, neither rapid
streptococcal tests nor surface cultures can differ-
entiate the streptococcal carrier state from invasive
infection. The carrier state is a key factor in solving
the riddle of who should and should not receive
antibiotic treatment for pharyngitis. Some experts
have suggested that low-colony-count infections
invariably represent a carrier state rather than
invasive infection [8]. This has not proven to be the
case, however, as low-count infections have
shown rates of streptococcal antibody responses
comparable to infectionswith higher colony counts
[9]. Hence, the development of further diagnostic
tests to differentiate invasive infections from
carrier status is of substantial importance.
CURRENT STREPTOCOCCAL TESTS
Rapid streptococcal testing can be performed
using various methods. Currently, most com-
mercial tests are immunoassays with a sensiti-
vity of 70–95% (average 85%) and a speciﬁcity
of 95–99% [10–15]. The accuracy of rapid testing
depends to some degree on the comparators
used. The reference standard comparator has
been culture on sheep blood agar with subse-
quent conﬁrmation by a secondary method such
as direct ﬂuorescent antibody testing. The dur-
ation of back-up culture is also important, with
48-h cultures showing 40% more positive
results than 24-h cultures [14]. Patient sub-
populations have shown distinct variations in
the accuracy of rapid streptococcal test results.
Low clinical probability scores [16] are associ-
ated with rapid streptococcal testing sensitivities
in the region of 70% [17]. Rapid streptococcal
test sensitivity increases to 94% in patients with
tonsillar exudate and no cough [17]. Higher-
clinical-probability situations, i.e., recent strep-
tococcal infection within the past 28 days, retain
baseline selectivity but actually predict a higher
sensitivity (c. 90%) for rapid testing [13]. Recent
antibiotic therapy increases false-negative rates
of rapid streptococcal testing, possibly by
decreasing colony counts [9].
Adult and paediatric specialty societies in the
USA have traditionally recommended conﬁrma-
tory culture for negative rapid streptococcal test
results [14]. Subsequent recommendations from
these societies have stated that rapid tests can be
used alone if they demonstrate results equival-
ent to those provided by culture methods [18].
Third-generation rapid streptococcal tests using
PCR-based methods, such as LightCycler ampliﬁ-
cation, appear to give equivalent or superior results
compared to culture and hence can be used alone
without back-up culture [19]. Physicians who use
rapid tests without culture back-up may wish to
compare their results with those of culture to
validate adequate sensitivity in their practice [18].
There is no such consensus in European guide-
lines concerning theuse of rapid tests. For example,
current guidelines from the UK recommend nei-
ther routine use of throat swabs nor rapid tests [20].
STREPTOCOCCAL TESTING IN
PRACTICE
It can be postulated that the introduction of rapid
testing could further ‘medicalise’ the illness of
pharyngitis and thereby lead to more patients
with this condition seeking medical care. While
this might increase the percentage of patients who
are treated only because of positive streptococcal
test results (either rapid tests or culturing), it
could also increase the total number of patients
being treated. Many patients in this total popula-
tion will have a self-limiting illness without
complications, i.e., because they are immunocom-
petent and can ﬁght off the illness, or because
their infection is viral and the positive strepto-
coccal test result was a false-positive result due to
a carrier status.
The only study to assess the change in antibiotic
prescribing in the USA since the introduction of
rapid streptococcal tests showed that prescribing
was improved (in terms of its appropriateness,
based on a positive test result) but not lowered in
total volume [21]. Moreover, this study did not
determine whether there was a change in the
denominator of the total patients being assessed
and treated.
Various guidelines and protocols have been
devised to create optimally cost-effective path-
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ways to categorise patients with pharyngitis
based on the likelihood of streptococcal infection,
and thus identify those likely to beneﬁt either
from rapid testing and treatment or from empir-
ical treatment strategies [16,22]. The stated goal
of many of these pathways is to minimise the
number of patients with non-streptococcal phar-
yngitis who receive empirical antibiotic therapy.
However, even the best of such protocols, which
do not rely on some type of testing programme,
invariably treat a large number of patients
without streptococcal pharyngitis with antibio-
tics [2,3].
Hence, based on existing clinical scores, the
optimal targeting of antibiotic therapy at the point
of consultation requires some type of bacterio-
logical testing, rather than a purely clinically
based approach to empirical treatment according
to risk group in unselected patients. Whether
optimal targeting at the point of consultation is
necessary and cost-effective when compared with
alternative strategies—such as delayed prescrib-
ing [23]), wherein the patient is asked to use
antibiotics only if symptoms are not resolving or
are getting worse—is still unclear. Immunocom-
promised patients and those with prior rheumatic
fever or other complicating factors fall outside of
such treatment protocols and should be evaluated
and treated more aggressively on a case-by-case
basis.
COST-EFFECTIVENESS OF
TREATMENT STRATEGIES
An evaluation of the cost-effectiveness of rapid
streptococcal testing compared with alternative
strategies for pharyngitis management should
take into account both the short-term aspects
(symptoms and complication rates) and long-
term considerations (e.g., antibiotic resistance).
To date, evidence regarding the cost-effective-
ness of rapid tests has come mainly from
modelling studies [24,25], and there have been
few data from prospective clinical trials. Fur-
thermore, there has been no direct measurement
of utilities based on trial data; no modelling of
costs of antibiotic resistance; questionable
assumptions (e.g., ‘observation’ is the best strat-
egy in adults if the utilities are 0.97 rather than
0.95, and quinsy occurs in less than
1.4%—which seems likely from UK data
[23,26); and no comparison with ‘delayed’ or
safety-net prescription, which limited data sug-
gest may have low complication rates for acute
sore throat, and lower costs than either culture
or observation alone [27,28].
Considering short-term, direct healthcare costs,
the most cost-effective strategy (ignoring any
potential legal aspects) is empirical antibiotic
treatment without microbiological testing [24].
However, this completely ignores the ‘down-
stream’ societal costs arising from antibiotic
resistance and individual patient adverse reac-
tions, and the wider issue of how such an
approach might promote unnecessary patient
consultations and hence increased visits and
antibiotic prescribing.
At the Mayo Clinic (Rochester, MN, USA), a
tiered approach to both diagnosis and treatment is
believed to offer themost effective and appropriate
use of healthcare resources without substantially
increasing the risk of failing to treat the majority of
infections that may beneﬁt from treatment (Fig. 1).
• The ﬁrst tier involves providing information for
patients via web-based and printed literature,
as well as education about when to seek care at
regular preventive visits.
• The second tier involves telephone triage by
nursing staff, which brings patients with high-
er clinical scores or other risk-factors into the
clinic for evaluation and recommends home
care for low-risk patients.
• The third tier involves a nursing-based protocol
for the treatment of low-risk patients using
rapid testing, with an automated system that
sends the appropriate prescription to their
pharmacy of choice. This efﬁciently provides
medication only to those with positive test
results and does not leave the patient with a
choice of whether to ﬁll a prescription or not,
or the provider with the responsibility of
ﬁnding and prescribing for all patients with
positive results.
• The fourth tier involves full clinical evaluation
by the physician of the sickest patients.
According to this approach, rapid testing of all
patients who are treated provides the additional
information that is needed when a patient has
recurrent pharyngitis and helps to risk-stratify
family members with symptoms. The system
works substantially better when incentives are
aligned for both the patient and provider—i.e., in
environments where the patient shoulders a
percentage of the treatment cost, and the provider
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has no incentive to treat or see higher numbers of
patients.
The upper and lower tiers of this model, i.e.,
patient education about when they do not need to
consult a physician and physician evaluation of the
sickest patients, are likely to be widely applicable
across environments. Differences among health-
care systems are more likely to be apparent in the
management of patients at intermediate risk. In
particular, until there is more evidence about how
to identify different risk groups, the effectiveness
of antibiotics in such subgroups, and the most
efﬁcient use of rapid tests, the variation in man-
agement of patients is likely to continue.
In terms of antibiotic selection, penicillin,
amoxycillin or a macrolide (for those who are
penicillin-allergic) are logical ﬁrst-line choices for
the treatment of low-risk patients (Table 1).
Patients with recurrent illness within 30 days or
with other complicating factorsmay best be treated
with a cephalosporin or amoxycillin-clavulanate ,
and patients allergic to these classes may best be
treatedwith clindamycin or amacrolide. The use of
amoxycillin is recommended by some authorities,
but is controversial for children and adolescents, in
view of the risk of rash among those with Epstein–
Barr Virus infections (glandular fever).
CONCLUSION
Of the current testing methods for pharyngitis, the
most cost-effective approach is rapid testing with-
out back-up culture, while the least cost-effective
approach is rapid testing with back-up culture.
Currently, the best practice where testing is per-
formed would include rapid testing only for those
patients in whom group A b-haemolytic strepto-
coccal infection is clinically likely or for those who
have any symptoms plus direct contact exposure.
The method of choice is a PCR-based rapid test
without back-up culture, or immunoassay with
back-up culture. Unlike other clinical situations in
which PCR-based testing can lead to more clinical
cures plus eradication of the transmission pool, the
main advantage of rapid streptococcal testing is
that it allows the practitioner to treat only those
cases of pharyngitis that are caused byGABHS and
to avoid prescribing antibiotics for viral infections.
The availability of same-day results allows the
practitioner and patient reasonable certainty that
those who will beneﬁt from antibiotic therapy will
receive it promptly and those who do not need it
will avoid unnecessary treatment. This, in turn,
could be cost-saving, potentially prevent un-
needed side-effects, and decrease antibiotic resist-
ance by decreasing the number of unnecessary
antibiotic prescriptions for viral upper respiratory
tract infections. However, given that the vast
majority of patients will not suffer complications
and have a self-limiting illness, it is unclear
whether such a strategy of using rapid tests is
better than empirical management with analgesic
support only (i.e., no initial offer of antibiotics)with
Table 1. Treatment protocols for streptococcal pharyngitis
Positive rapid test or
culture test
Patients with positive results
treated by algorithm
Automated system sends
prescription to pharmacy
First-line treatment Penicillin or amoxycillin
If allergic: macrolide
Second-line treatment Amoxycillin–clavulanate
or cephalosporin
If allergic: macrolide if patient
in low-risk situation;
clindamycin if risk–beneﬁt
justiﬁes this on an
individual basis
* Rapid test: third-generation PCR-based test without back-up culture or 
less sensitive test with back-up culture.  
Abbreviations: NP = nurse practitioner; PA = physician’s assistant; 
PCR = polymerase chain reaction.
Physician (or NP/PA): 
Face-to-face evaluation of sickest 
patients or those with other risk factors
Registered nurse: 
Face-to-face evaluation using protocol and 
rapid strep test*of low risk patients 
Registered nurse: 
Telephone triage of patients:  
home care for low risk, office visit for others 
Information for patients:
web-based, printed literature, education during well visits 
Fig. 1. Treatment strategy for streptococcal pharyngitis
using a tiered ‘test-and-treat’ approach. This protocol
works best when incentives are aligned for both the
provider network and the patient. *Rapid test: third-
generation PCR-based test without back-up culture or less
sensitive test with back-up culture. NP, nurse practitioner;
PA, physician’s assistant.
6 Clinical Microbiology and Infection, Volume 12 Supplement 9, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (suppl 9), 3–7
instruction for review should symptoms become,
worse or not resolve, or alternatively, using the
strategy of delayed antibiotic prescription.
There is a need for direct evidence of the
magnitude of beneﬁt to patients from rapid strep-
tococcal testing, obtained from randomised trials
comparing the use of tests with the main alterna-
tives, which should include evidence about the
‘medicalisation’ of illness and total antibiotic use.
The spectrum bias of tests should also be evaluated
in different populations, since the validation char-
acteristics vary according to the prevalence and
severity of the disease. Better evidence concerning
alternative strategies is also required, for instance,
a more valid clinical decision rule based on immu-
nological evidence as a reference standard, and
delayed prescribing of antibiotics.
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